Research location

Ube

Yamaguchi, Japan

Published trials73

Site observations75

Linked trials published73

Page1 / 2

Research activity in Ube

Yamaguchi, Japan

CureCurrent currently publishes aggregate city-level research activity for this location: 73 trials and 75 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Ube

73 linked trials · page 1 of 2

Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic CancersNCT07493304 · 2026-08-26 · 1 site observation

REGN7508 in Adult Participants for Prevention of Cancer-Associated ThrombosisNCT07410117 · 2026-03-09 · 1 site observation

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary DiseaseNCT07363694 · 2026-02-11 · 1 site observation

A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)NCT07359846 · 2026-01-20 · 1 site observation

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNCT07222566 · 2026-01-06 · 1 site observation

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionNCT07063745 · 2026-01-02 · 1 site observation

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.NCT07053423 · 2025-09-22 · 1 site observation

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic PhenotypeNCT07190209 · 2025-09-16 · 1 site observation

A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With SchizophreniaNCT06882785 · 2025-06-10 · 1 site observation

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)NCT06925737 · 2025-05-13 · 1 site observation

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)NCT06452277 · 2024-08-28 · 1 site observation

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]NCT06422143 · 2024-06-10 · 1 site observation

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)NCT06170788 · 2023-12-15 · 1 site observation

Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk AsthmaNCT06676319 · 2024-11-07 · 1 site observation

ACTIVE_NOT_RECRUITING

Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With AsthmaNCT06609239 · 2024-09-30 · 1 site observation

ENROLLING_BY_INVITATION

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe AsthmaNCT06102005 · 2023-10-16 · 1 site observation

A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 DiabetesNCT06010004 · 2023-09-28 · 2 site observations

Study to Evaluate Clinical Real World Outcomes of Lorlatinib After Alectinib in ALK-Positive NSCLC Japanese PatientsNCT04979988 · 2021-08-02 · 1 site observation

Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg PenNCT04940065 · 2021-06-30 · 1 site observation

Special Drug Use-results Surveillance of Tabrecta TabletsNCT04575025 · 2020-11-02 · 1 site observation

Long Term Special Drug Use-results Surveillance for Mayzent in SPMS PatientsNCT04593927 · 2020-10-28 · 1 site observation

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117 · 2020-10-19 · 1 site observation

ACTIVE_NOT_RECRUITING

Prevalence of HRR-related Genes Mutations and Prognosis in Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients in Real World SettingNCT04425200 · 2020-07-29 · 1 site observation

Study of a High-Dose Aflibercept in Participants With Diabetic Eye DiseaseNCT04429503 · 2020-06-29 · 1 site observation

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)NCT04191096 · 2020-02-12 · 1 site observation

KW-3357 Study in Patients With Early Onset Severe PreeclampsiaNCT04182373 · 2019-11-19 · 1 site observation

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by SurgeryNCT04026412 · 2019-10-08 · 1 site observation

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)NCT03834493 · 2019-07-28 · 1 site observation

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)NCT03898180 · 2019-05-06 · 1 site observation

Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)NCT03834506 · 2019-05-02 · 1 site observation

Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)NCT03834519 · 2019-05-02 · 1 site observation

A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung CancerNCT03807778 · 2019-02-04 · 1 site observation

ACTIVE_NOT_RECRUITING

Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC SubjectsNCT03631199 · 2018-12-21 · 1 site observation

Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-ANCT03447769 · 2018-03-16 · 1 site observation

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial CarcinomaNCT03374488 · 2017-12-22 · 1 site observation

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)NCT03260894 · 2017-12-07 · 1 site observation

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)NCT03361865 · 2017-12-04 · 1 site observation

Heart Failure and Sudden Cardiac Death Japan RegistryNCT03185832 · 2017-07-21 · 1 site observation

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)NCT03142334 · 2017-06-09 · 1 site observation

A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)NCT03066778 · 2017-05-02 · 1 site observation

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLCNCT03052608 · 2017-04-27 · 1 site observation

ACTIVE_NOT_RECRUITING

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyNCT02960022 · 2016-12-22 · 1 site observation

ACTIVE_NOT_RECRUITING

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate CancerNCT02799602 · 2016-11-30 · 1 site observation

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate CancerNCT02918968 · 2016-11-02 · 1 site observation

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)NCT02677896 · 2016-03-09 · 1 site observation

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal DiseaseNCT02512068 · 2015-08-07 · 1 site observation

A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of the OL-BF-001 for Severe EmphysemaNCT02470052 · 2015-08-01 · 1 site observation

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)NCT02414139 · 2015-06-11 · 1 site observation

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)NCT02411448 · 2015-05-06 · 1 site observation

ACTIVE_NOT_RECRUITING

Japanese Phase 3 Study of Aflibercept in Neovascular Glaucoma PatientsNCT02396316 · 2015-04-02 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.